Augusto Mota

Dr. Augusto Mota

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
lila teixeira araujolila teixeira araujo
lila teixeira araujo
CMCarolina Macedo
Carolina Macedo
PDPATRICIA KAUANNA FONSECA DAMASCENO
PATRICIA KAUANNA FONSECA DAMASCENO
ÍNÍtalo Costa Neves
Ítalo Costa Neves
CLCarla Souza de Lima
Carla Souza de Lima
Milena SoaresMilena Soares
Milena Soares
Spinal cord injury (SCI) remains an important public health problem which often causes permanent loss of muscle strength, sensation, and function below the site of the injury, generating physical, psychological, and social impacts throughout the lives of the affected individuals, since there are no effective treatments available. The use of stem cells has been investigated as a therapeutic approach for the treatment of SCI. Although a significant number of studies have been conducted in pre-clinical and clinical settings, so far there is no established cell therapy for the treatment of SCI. One aspect that makes it difficult to evaluate the efficacy is the heterogeneity of experimental designs in the clinical trials that have been published. Cell transplantation methods vary widely among the trials, and there are still no standardized protocols or recommendations for the therapeutic use of stem cells in SCI. Among the different cell types, mesenchymal stem/stromal cells (MSCs) are the most frequently tested in clinical trials for SCI treatment. This study reviews the clinical applications of MSCs for SCI, focusing on the critical analysis of 17 clinical trials published thus far, with emphasis on their design and quality. Moreover, it highlights the need for more evidence-based studies designed as randomized controlled trials and potential challenges to be addressed in context of stem cell therapies for SCI.

9 April 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
ASAndrey Soares
Andrey Soares
FMFernando Sabino Marques Monteiro
Fernando Sabino Marques Monteiro
KTKarine Martins da Trindade
Karine Martins da Trindade
ASAdriano Gonçalves e Silva
Adriano Gonçalves e Silva
ACAna Paula Garcia Cardoso
Ana Paula Garcia Cardoso
SZStênio C. Zequi
Stênio C. Zequi
Purpose: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. Methods: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours. The results were compared with the literature and graded according to the level of evidence. Results: Adjuvant treatments benefit patients with a high risk of recurrence after surgery, and the agents used are pembrolizumab and sunitinib, with a preference for pembrolizumab. Neoadjuvant treatment is exceptional, even in initially unresectable cases. First-line treatment is mainly based on tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); the choice of treatment is based on the International Metastatic Database Consortium (IMCD) risk score. Patients at favourable risk receive ICIs in combination with TKIs. Patients classified as intermediate or poor risk receive ICIs, without preference for ICI + ICIs or ICI + TKIs. Data on nonclear cell renal cancer treatment are limited. Active surveillance has a place in treating favourable-risk patients. Either denosumab or zoledronic acid can be used for treating metastatic bone disease. Conclusion: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.

1 August 1999 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
AGAuro del Giglio
Auro del Giglio
LCL.J.M. Costa
L.J.M. Costa
HPH. Pinczowski
H. Pinczowski
PVP.C.S. Varella
P.C.S. Varella
JLJ.R. Luzzi
J.R. Luzzi
CSC. Sampaio
C. Sampaio

26 October 2023 in medRxiv
Verified
Preprint
Open access
PDF file
AMAugusto Mota
Augusto Mota
VFValdir C. Sant’ana Filho
Valdir C. Sant’ana Filho
CHCarolyn M. Hendrickson
Carolyn M. Hendrickson
RDRachel M. DeVay
Rachel M. DeVay
MDMatt Donne
Matt Donne
WCWendy Cousin
Wendy Cousin
OBJECTIVES: Disulfiram, a low-cost generic drug used for alcohol dependence, holds the potential to mitigate disease progression in patients with moderate COVID-19 by targeting inflammasomes. This study aimed to evaluate the clinical efficacy and safety of disulfiram when administered alongside standard of care for the treatment of hospitalized individuals with moderate COVID-19. DESIGN: A randomized, double-blind, placebo-controlled trial. SETTING: Conducted at four clinical sites in Brazil between December 2020 and August 2021. PARTICIPANTS: 140 participants aged 35 and older with laboratory-confirmed SARS-CoV-2 infection, hospitalized for ≤5 days with moderate symptoms of COVID-19 were enrolled, 137 were randomized. INTERVENTION: Participants were randomized in a 1:1 ratio to receive a daily dose of 500 mg of disulfiram (N=68) or placebo (N=69) for 14 days while receiving the current standard of care. Randomization was stratified by age and comorbidities (hypertension, diabetes, and BMI ≥35). MEASUREMENTS AND MAIN RESULTS: The primary outcome, median time to clinical improvement [95% CI] did not significantly differ between groups (disulfiram: 3.5 [3.00, 4.00] days; placebo: 4 [3.00, 5.00] days; P=.73). Key secondary outcomes, such as mean days (SD) on supplemental oxygen [disulfiram: 4.4 (6.61) days; placebo: 3.7 (5.80) days, P=.34], median (95% CI) time to hospital discharge [disulfiram: 6.0 (5.00, 8.00) days, placebo: 5.0 (4.00, 7.00)], proportion of participants discharged by day 8 [disulfiram (68%), placebo (63%), odds ratio: 0.801], and proportion of participants who clinically worsened [disulfiram (21%), placebo (19%), P=.79], did not reveal significant differences. While the incidence of adverse events was higher in the disulfiram group, serious adverse events and 28-day mortality were comparable between the two groups. Conclusions: Although disulfiram was found to be safe in hospitalized patients with moderate COVID-19, it did not shorten the time to clinical improvement. These findings do not support the use of disulfiram alongside standard of care in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04594343 Key Points: Background: Disulfiram has been proposed to mitigate disease progression in patients with COVID-19 by targeting the inflammasomes. Question: Does disulfiram, a generic drug used for alcohol use disorder, reduce the time to clinical improvement or reduce the risk of severe disease in hospitalized patients with moderate COVID-19 and with comorbidities when added to the standard of care? Findings: In this double-blind, placebo-controlled randomized clinical trial of adults hospitalized with moderate COVID-19 in Brazil, the addition of an oral disulfiram treatment to the standard of care was safe. Still, it did not decrease the time to clinical improvement. Meaning: The study findings do not support the use of disulfiram in hospitalized patients with moderate COVID-19 in addition to the standard of care.

1 March 2026 in JCO Global Oncology
Verified
Journal Article
Open access
FMFernando Sabino Marques Monteiro
Fernando Sabino Marques Monteiro
VSVinicius Carrera Souza
Vinicius Carrera Souza
KTKarine Martins da Trindade
Karine Martins da Trindade
ASAdriano Gonçalves e Silva
Adriano Gonçalves e Silva
AMAugusto Mota
Augusto Mota
ASAndrey Soares
Andrey Soares
PURPOSE: Prostate cancer is the most prevalent cancer in men worldwide. As new treatments become available, costs also increase, and patients from lower-middle-income countries do not have access to those treatments due to cost restriction and governmental approval. However, several non–survival-prolonging treatments (nspTx) continue to be offered to patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: We gathered retrospective data from patients with mCRPC treated under the Brazilian Public Health System (BPHS) from 2017 to 2023. Our analysis concentrated on assessing the treatment plans, the median duration of treatment (mDoT), and the costs associated with these plans. The main aim of this study was to clarify the overall expenses, timing, and types of therapies provided to patients with mCRPC. RESULTS: A cohort of 38,851 patients with mCRPC showed a mDoT of 20.5 months and total castration-resistant treatment costs of $333,200,939 US dollars (USD). Among them, 31,430 (81%) received survival-prolonging treatments (spTx), while 7,421 (19%) were given nspTx. The spTx group had a mDoT of 19.8 months, with total spending of $269,892,761 USD and an average cost per patient of $8,587.11 USD. The nspTx group's mDoT was 20.5 months, costing $63,308,180 USD in total and $8,530.95 USD per patient. Exploratory analysis indicated that funds spent on nonsurvival treatments for one patient could cover generic cabazitaxel (20 mg/m 2 once every 21 days, six cycles) for approximately two patients with mCRPC. CONCLUSION: This long-term analysis of the BPHS treatment of mCRPC shows substantial spending on spTx and nspTx. Although most patients received recommended spTx, 19% received nspTx at similar costs. Results indicate the need for reforms to prioritize evidence-based treatments in resource-limited settings.

20 June 2026 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
QTQuoc-Dien Trinh
Quoc-Dien Trinh
DGDaniel James George
Daniel James George
NSNeil Shore
Neil Shore
EVEgils Vjaters
Egils Vjaters
DODavid Olmos
David Olmos
FSFred Saad
Fred Saad
Background This analysis reports efficacy and safety data in the subgroup of Black patients from the ARANOTE phase 3 trial. Methods Patients starting on androgen-deprivation therapy (ADT) were randomised 2:1 to receive darolutamide 600 mg twice daily or placebo. Of the total ARANOTE population (N = 669), 65 patients (10%; darolutamide, n = 41; placebo, n = 24) were Black. Results In Black patients, darolutamide + ADT improved radiological progression-free survival (rPFS), reducing the risk of radiological progression or death by 49% vs ADT alone, consistent with the overall population. Conclusions In Black patients from ARANOTE, darolutamide was associated with improvement in rPFS.